Initial metabolic tumor volume measured by 18F-FDG PET/CT can predict the outcome of osteosarcoma of the extremities

Journal of Nuclear Medicine

Volumn 54, Issue 10, 2013, Pages 1725-1732

  Byun, Byung Hyun ^a   Kong, Chang Bae ^a   Park, Jihyun ^a   Seo, Youngseok ^a   Lim, Ilhan ^a   Choi, Chang Woon ^a   Cho, Wan Hyeong ^a   Jeon, Dae Geun ^a   Koh, Jae Soo ^a   Lee, Soo Yong ^a   Lim, Sang Moo ^a  

^a Korea Cancer Center Hospital   (South Korea)

Author keywords

Metabolic tumor volume; Osteosarcoma; PET CT; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CHILD; CLINICAL FEATURE; COHORT ANALYSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMAGING AND DISPLAY; LIMB; MAJOR CLINICAL STUDY; MALE; METABOLIC TUMOR VOLUME; METASTASIS; METASTASIS FREE SURVIVAL; NUCLEAR MAGNETIC RESONANCE SCANNER; ONCOLOGICAL PARAMETERS; OSTEOSARCOMA; PET-CT SCANNER; POSTOPERATIVE CARE; PREOPERATIVE CARE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; STANDARDIZED UPTAKE VALUE; TOTAL LESION GLYCOLYSIS; TREATMENT RESPONSE; TUMOR VOLUME; 18F-FDG; COMPUTER ASSISTED TOMOGRAPHY; METABOLISM; MULTIMODAL IMAGING; PATHOLOGY; PET/CT; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; SCINTISCANNING; SURVIVAL; YOUNG ADULT; DIAGNOSTIC USE;

18F-FDG; METABOLIC TUMOR VOLUME; OSTEOSARCOMA; PET/CT; SURVIVAL;

ADOLESCENT; ADULT; CHILD; EXTREMITIES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MULTIMODAL IMAGING; OSTEOSARCOMA; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN; YOUNG ADULT;

EID: 84891690367     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.117697     Document Type: Article

References (38)

1. Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res. 2009;152:3-13.
2. Bacci G, Picci P, Ferrari S, et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities: results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer. 1993;72:3227-3238.
3. Marcove RC, Mike V, Hajek JV, Levin AG, Hutter RV. Osteogenic sarcoma under the age of twenty-one: a review of one hundred and forty-five operative cases. J Bone Joint Surg Am. 1970;52: 411-423.
4. Greene FL. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer-Verlag; 2002:187-192.
5. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980;Nov-Dec: 106-120.
6. Glasser DB, Lane JM, Huvos AG, Marcove RC, Rosen G. Survival, prognosis, and therapeutic response in osteogenic sarcoma: The Memorial Hospital experience. Cancer. 1992;69:698-708.
7. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol. 1994;12:423-431.
8. Franzius C, Sciuk J, Daldrup-Link HE, Jurgens H, Schober O. FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. Eur J Nucl Med. 2000;27:1305-1311.
9. 18F-FDG PET/CT indices, after one course and at the completion of neoadjuvant chemotherapy, in children and young adults with osteosarcoma. Eur J Nucl Med Mol Imaging. 2012;39:39-49.
10. 18F-FDG PET and MR imaging. J Nucl Med. 2009;50:1435-1440.
11. 18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma. J Nucl Med. 2009;50:340-347.
12. 18F-FDG uptake in primary osteosarcoma after but not before chemotherapy: a possible association with autocrine motility factor/phosphoglucose isomerase expression. Clin Exp Metastasis. 2008;25:427-435.
13. 18FFDG PET/CT improves the prediction of prognosis in small cell lung cancer. Eur J Nucl Med Mol Imaging. 2012;39:925-935.
14. Yan H, Wang R, Zhao F, et al. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced non-small cell lung cancer treated by nonsurgical therapy. Acta Radiol. 2011;52:646-650.
15. 18F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer. Clin Cancer Res. 2009;15:5861-5868.
16. 18F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection. Ann Surg. 2013;257:364-370.
17. Larson SM, Erdi Y, Akhurst T, et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging: the visual response score and the change in total lesion glycolysis. Clin Positron Imaging. 1999;2:159-171.
18. Chen HH, Chiu NT, Su WC, Guo HR, Lee BF. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Radiology. 2012;264:559-566.
19. Kim MS, Cho WH, Song WS, Lee SY, Jeon DG. Time dependency of prognostic factors in patients with stage II osteosarcomas. Clin Orthop Relat Res. 2007;463: 157-165.
20. Carrle D, Bielack SS. Current strategies of chemotherapy in osteosarcoma. Int Orthop. 2006;30:445-451.
21. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776-790.
22. Carsi B, Rock MG. Primary osteosarcoma in adults older than 40 years. Clin Orthop Relat Res. 2002;397:53-61.
23. Coffin CM, Lowichik A, Zhou H. Treatment effects in pediatric soft tissue and bone tumors: practical considerations for the pathologist. Am J Clin Pathol. 2005;123:75-90.
24. 18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: is a single standardized uptake value threshold approach appropriate? J Nucl Med. 2006;47: 1808-1812.
25. Kim MS, Lee SY, Cho WH, et al. Initial tumor size predicts histologic response and survival in localized osteosarcoma patients. J Surg Oncol. 2008;97: 456-461.
26. Bieling P, Rehan N, Winkler P, et al. Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol. 1996;14:848-858.
27. Cain KC, Lange NT. Approximate case influence for the proportional hazards regression model with censored data. Biometrics. 1984;40:493-499.
28. Therneau T, Grambsch P, Fleming T. Martingale-based residuals for survival models. Biometrika. 1990;77:147-160.
29. Lemeshow S, Hosmer DW Jr. A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol. 1982;115:92-106.
30. Sauerbrei W, Schumacher M. A bootstrap resampling procedure for model building: application to the Cox regression model. Stat Med. 1992;11:2093-2109.
31. Harrell FE Jr, Lee KL, Mark DB. Multivariate prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361-387.
32. Jeon DG, Song WS. How can survival be improved in localized osteosarcoma? Expert Rev Anticancer Ther. 2010;10:1313-1325.
33. Goorin AM, Schwartzentruber DJ, Devidas M, et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol. 2003; 21:1574-1580.
34. 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer. Lung Cancer. 2011;73: 332-337.
35. Mankin HJ, Hornicek FJ, Rosenberg AE, Harmon DC, Gebhardt MC. Survival data for 648 patients with osteosarcoma treated at one institution. Clin Orthop Relat Res. 2004;429:286-291.
36. Wunder JS, Bull SB, Aneliunas V, et al. MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study. J Clin Oncol. 2000;18:2685-2694.
37. Broström LA, Strander H, Nilsonne U. Survival in osteosarcoma in relation to tumor size and location. Clin Orthop Relat Res. 1982;167:250-254.
38. Szendroi M, Papai Z, Koos R, Illes T. Limb-saving surgery, survival, and prognostic factors for osteosarcoma: the Hungarian experience. J Surg Oncol. 2000; 73:87-94.